CyPath® Lung Sales Surge 200% Year-Over-Year, Boosting Commercial Momentum
BIAF sits 21% above its 52-week low of $0.693.
Summary
bioAffinity Technologies reported significant commercial sales growth for its CyPath® Lung diagnostic, with Q2 2026 sales up over 200% year-over-year and 30% quarter-over-quarter, indicating strong market adoption.
Key Events · Product Development and Regulatory · BIAF
-
Record Sales Growth for CyPath® Lung
Commercial sales volume for CyPath® Lung increased over 200% year-over-year in Q2 2026 and more than 30% compared to Q1 2026.
-
Expanding Physician Adoption
The number of physician offices ordering CyPath® Lung grew by 155% year-over-year, with nearly 3,000 tests performed since commercial launch.
-
Strategic Initiatives Underway
The company is pursuing a large-scale clinical study, expanding into oncology, and developing diagnostics for asthma and COPD.
-
Positive Ahead of Q2 Earnings
This strong operational update provides a positive outlook for the upcoming Q2 2026 financial results, which are expected in August.
Analysis · BIAF · Industrial Applications And Services
bioAffinity Technologies reported significant commercial sales growth for its CyPath® Lung diagnostic, with Q2 2026 sales up over 200% year-over-year. This strong operational performance is critical for the micro-cap company, especially following its recent $3.2 million public offering in June, which was necessary to address a 'going concern' warning and extend its cash runway beyond June 2026. The accelerating sales demonstrate market adoption and provide positive momentum as the company approaches its Q2 earnings report.
At the time of this filing, BIAF was trading at $0.84 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.69 to $13.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.